202 related articles for article (PubMed ID: 19572232)
1. Small intestinal neuroendocrine tumors: prognostic factors and survival.
Bergestuen DS; Aabakken L; Holm K; Vatn M; Thiis-Evensen E
Scand J Gastroenterol; 2009; 44(9):1084-91. PubMed ID: 19572232
[TBL] [Abstract][Full Text] [Related]
2. Survival and prognostic factors in well-differentiated pancreatic neuroendocrine tumors.
Boyar Cetinkaya R; Vatn M; Aabakken L; Bergestuen DS; Thiis-Evensen E
Scand J Gastroenterol; 2014 Jun; 49(6):734-41. PubMed ID: 24679166
[TBL] [Abstract][Full Text] [Related]
3. A nomogram to assess small-intestinal neuroendocrine tumor ('carcinoid') survival.
Modlin IM; Gustafsson BI; Pavel M; Svejda B; Lawrence B; Kidd M
Neuroendocrinology; 2010; 92(3):143-57. PubMed ID: 20733279
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.
Panzuto F; Nasoni S; Falconi M; Corleto VD; Capurso G; Cassetta S; Di Fonzo M; Tornatore V; Milione M; Angeletti S; Cattaruzza MS; Ziparo V; Bordi C; Pederzoli P; Delle Fave G
Endocr Relat Cancer; 2005 Dec; 12(4):1083-92. PubMed ID: 16322345
[TBL] [Abstract][Full Text] [Related]
5. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors.
Arnold R; Wilke A; Rinke A; Mayer C; Kann PH; Klose KJ; Scherag A; Hahmann M; Müller HH; Barth P
Clin Gastroenterol Hepatol; 2008 Jul; 6(7):820-7. PubMed ID: 18547872
[TBL] [Abstract][Full Text] [Related]
6. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut.
Strosberg J; Gardner N; Kvols L
Neuroendocrinology; 2009; 89(4):471-6. PubMed ID: 19174605
[TBL] [Abstract][Full Text] [Related]
7. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract.
Rorstad O
J Surg Oncol; 2005 Mar; 89(3):151-60. PubMed ID: 15719376
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).
Martin-Perez E; Capdevila J; Castellano D; Jimenez-Fonseca P; Salazar R; Beguiristain-Gomez A; Alonso-Orduña V; Martinez Del Prado P; Villabona-Artero C; Diaz-Perez JA; Monleon A; Marazuela M; Pachon V; Sastre-Valera J; Sevilla I; Castaño A; Garcia-Carbonero R
Neuroendocrinology; 2013; 98(2):156-68. PubMed ID: 23988576
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.
Pape UF; Berndt U; Müller-Nordhorn J; Böhmig M; Roll S; Koch M; Willich SN; Wiedenmann B
Endocr Relat Cancer; 2008 Dec; 15(4):1083-97. PubMed ID: 18603570
[TBL] [Abstract][Full Text] [Related]
10. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.
Korse CM; Bonfrer JM; Aaronson NK; Hart AA; Taal BG
Neuroendocrinology; 2009; 89(3):296-301. PubMed ID: 18840995
[TBL] [Abstract][Full Text] [Related]
11. A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress.
Modlin IM; Champaneria MC; Chan AK; Kidd M
Am J Gastroenterol; 2007 Jul; 102(7):1464-73. PubMed ID: 17391319
[TBL] [Abstract][Full Text] [Related]
12. The significance of CD44 expression in gastrointestinal neuroendocrine tumors.
Lai CH; Shan YS; Sy ED; Hsieh YH; Tsai HW; Lee JC; Lin PW
Hepatogastroenterology; 2005; 52(64):1071-6. PubMed ID: 16001632
[TBL] [Abstract][Full Text] [Related]
13. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors.
Strosberg J; Nasir A; Coppola D; Wick M; Kvols L
Hum Pathol; 2009 Sep; 40(9):1262-8. PubMed ID: 19368957
[TBL] [Abstract][Full Text] [Related]
14. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors.
Chou WC; Chen JS; Hung YS; Hsu JT; Chen TC; Sun CF; Lu CH; Hwang TL
Anticancer Res; 2014 Oct; 34(10):5661-9. PubMed ID: 25275071
[TBL] [Abstract][Full Text] [Related]
15. Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors.
Modlin IM; Gustafsson BI; Drozdov I; Nadler B; Pfragner R; Kidd M
Ann Surg Oncol; 2009 Feb; 16(2):487-98. PubMed ID: 19050963
[TBL] [Abstract][Full Text] [Related]
16. Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours.
Zandee WT; Kamp K; van Adrichem RC; Feelders RA; de Herder WW
Eur J Endocrinol; 2016 Nov; 175(5):361-6. PubMed ID: 27491374
[TBL] [Abstract][Full Text] [Related]
17. Varying malignant potential of appendiceal neuroendocrine tumors: importance of histologic subtype.
Hsu C; Rashid A; Xing Y; Chiang YJ; Chagpar RB; Fournier KF; Chang GJ; You YN; Feig BW; Cormier JN
J Surg Oncol; 2013 Feb; 107(2):136-43. PubMed ID: 22767417
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma.
Durante C; Boukheris H; Dromain C; Duvillard P; Leboulleux S; Elias D; de Baere T; Malka D; Lumbroso J; Guigay J; Schlumberger M; Ducreux M; Baudin E
Endocr Relat Cancer; 2009 Jun; 16(2):585-97. PubMed ID: 19240182
[TBL] [Abstract][Full Text] [Related]
19. The impact of stage and cell type on the prognosis of pulmonary neuroendocrine tumors.
Lim E; Yap YK; De Stavola BL; Nicholson AG; Goldstraw P
J Thorac Cardiovasc Surg; 2005 Oct; 130(4):969-72. PubMed ID: 16214506
[TBL] [Abstract][Full Text] [Related]
20. Prognostic clinicopathologic factors in longitudinally followed patients with metastatic small bowel carcinoid tumors.
Curran T; Tulin-Silver S; Patel K; Ward S; Schneiderman M; Harpaz N; Schwartz M; Itzkowitz S; Warner RR; Kim MK
Pancreas; 2011 Nov; 40(8):1253-7. PubMed ID: 21975435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
